Remove .Net Remove 2016 Remove Marketing Remove Report
article thumbnail

Qualstar Continues To Look At Strategic Options

socalTECH

Simi Valley-based Qualstar , the developer of data storage and high efficiency power supplies, says it continues to look at "strategic options" for the business, as it reported yet another quarter of declining revenues. for the quarter ended December 31, 2016. The company reported a net loss of $1.2 READ MORE>>.

Layoffs 113
article thumbnail

NantHealth Files For IPO

socalTECH

NantHealth said it intends to list on the NASDAQ Global Market as NH. NantHealth reported a net loss of $71.6M The filing is the first IPO filing for a Southern California technology firm so far in 2016. The IPO is being underwritten by Jeffries, Cowen and Company, First Analysis Securities Co.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Xconomy Special Report: 12 San Diego Tech Startup to Watch in 2017

Xconomy

View the Slideshow A little more than a year ago, amid a resurgence in San Diego’s software sector, Xconomy identified a baker’s dozen of local tech companies to watch in 2016. I widened my net this year. The results were so encouraging, we’re doing it again.

article thumbnail

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

Xconomy

And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. The CRISPR news this week doesn’t need a metaphor; the drama that MIT Technology Review reported can stand alone. STAT found the figures in Editas’s quarterly earnings report. Talk about sacrifice.

article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing. A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017. Alex Lash contributed to this report. . —Pfizer wasn’t done after scooping up Medivation.

Pricing 40